Resources

15 April 2021, 3-5 pm 1st T2EVOLVE Multistakeholder Meeting: The purpose of this meeting is to engage external stakeholders early in the project, to help shape a T2EVOLVE stakeholder community, and foster opportunities for additional collaborations which...

The T2EVOLVE project had its first public appearance at the EHA-EBMT 3rd European CAR T-cell Meeting, with a workshop on February 5, from 7:00 PM CET entitled ‘How to rapidly move new CAR-Ts forward from bench to bedside? Key questions and answers!’

T2EVOLVE is a breakthrough alliance of academic and industry leaders in cancer immunotherapy which started in January 2021, under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and to increase...